132 related articles for article (PubMed ID: 38193596)
21. Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials.
Tosetto A; Neff A; Lentz SR; Santagostino E; Nemes L; Sathar J; Meijer K; Chowdary P; Shen C; Landorph A; Hampton K
Haemophilia; 2020 May; 26(3):450-458. PubMed ID: 32293786
[TBL] [Abstract][Full Text] [Related]
22. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis.
Mancuso ME; Reding MT; Negrier C; Kerlin BA; Rangarajan S; Simpson ML
Thromb Haemost; 2021 Aug; 121(8):1079-1086. PubMed ID: 33296943
[TBL] [Abstract][Full Text] [Related]
23. Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison.
Hakimi Z; Santagostino E; Postma MJ; Nazir J
Adv Ther; 2021 Feb; 38(2):1263-1274. PubMed ID: 33377987
[TBL] [Abstract][Full Text] [Related]
24. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
Lentz SR; Janic D; Kavakli K; Miljic P; Oldenburg J; C Ozelo M; Santagostino E; Suzuki T; Zupancic Šalek S; Korsholm L; Matytsina I; Tiede A
Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994
[TBL] [Abstract][Full Text] [Related]
25. Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII-treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study.
Escuriola Ettingshausen C; Katsarou O; Kotnik BF; Borel Derlon A; Schwarz R; Ypma PF; Matytsina I; Dey S; Schutgens REG
Haemophilia; 2022 Jan; 28(1):46-54. PubMed ID: 34791736
[TBL] [Abstract][Full Text] [Related]
26. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
[TBL] [Abstract][Full Text] [Related]
27. Budget impact analysis of Jivi (damoctocog alfa pegol, Bay 94-9027) in severe hemophilia A in Japan.
Fujii T; Kidoguchi Y; Takahashi N; Yu E; Ainiwaer D; Byrne A
J Med Econ; 2021; 24(1):218-225. PubMed ID: 33459088
[TBL] [Abstract][Full Text] [Related]
28. BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results.
Lalezari S; Reding MT; Pabinger I; Holme PA; Negrier C; Chalasani P; Shin HJ; Wang M; Tseneklidou-Stoeter D; Maas Enriquez M
Haemophilia; 2019 Nov; 25(6):1011-1019. PubMed ID: 31621991
[TBL] [Abstract][Full Text] [Related]
29. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
[TBL] [Abstract][Full Text] [Related]
30. Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trials.
Witarto BS; Visuddho V; Witarto AP; Sutanto H; Wiratama BS; Wungu CDK
F1000Res; 2021; 10():1049. PubMed ID: 35136579
[No Abstract] [Full Text] [Related]
31. Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).
Curry N; Albayrak C; Escobar M; Andre Holme P; Kearney S; Klamroth R; Misgav M; Négrier C; Wheeler A; Santagostino E; Shima M; Landorph A; Tønder SM; Lentz SR
Haemophilia; 2019 May; 25(3):373-381. PubMed ID: 30817066
[TBL] [Abstract][Full Text] [Related]
32. Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients.
You CW; Baek HJ; Park SK; Park YS; Shin HJ; Engl W; Tangada S
Blood Res; 2019 Sep; 54(3):198-203. PubMed ID: 31730687
[TBL] [Abstract][Full Text] [Related]
33. Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A.
Vashi P; Batt K; Klamroth R; Mancuso ME; Majewska R; Tiede A; Mantovani LG
J Blood Med; 2021; 12():935-943. PubMed ID: 34754257
[TBL] [Abstract][Full Text] [Related]
34. Long-term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect study in previously untreated patients.
Mathias M; Abashidze M; Abraham A; Belletrutti MJ; Carcao M; Chambost H; Chan AKC; Dubey L; Ducore J; Lambert T; Kavardakova N; Lohade S; Turea V; Wu JKM; Klukowska A
Haemophilia; 2023 Jul; 29(4):1005-1012. PubMed ID: 37335546
[TBL] [Abstract][Full Text] [Related]
35. Efmoroctocog Alfa: A Review in Haemophilia A.
Frampton JE
Drugs; 2016 Sep; 76(13):1281-1291. PubMed ID: 27487799
[TBL] [Abstract][Full Text] [Related]
36. Monitoring of different factor VIII replacement products using a factor VIII one-stage clotting assay on cobas t 511/711 analysers.
Ketteler C; Hoffmann I; Davidson S; Tiede A; Richter N
Haemophilia; 2021 Nov; 27(6):e704-e712. PubMed ID: 34590394
[TBL] [Abstract][Full Text] [Related]
37. Efmoroctocog Alfa: A Review in Haemophilia A.
Frampton JE
Drugs; 2021 Nov; 81(17):2035-2046. PubMed ID: 34743314
[TBL] [Abstract][Full Text] [Related]
38. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.
Aledort L; Milligan S; Watt M; Booth J
J Manag Care Spec Pharm; 2020 Apr; 26(4):492-503. PubMed ID: 32223610
[TBL] [Abstract][Full Text] [Related]
39. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A.
Nolan B; Mahlangu J; Perry D; Young G; Liesner R; Konkle B; Rangarajan S; Brown S; Hanabusa H; Pasi KJ; Pabinger I; Jackson S; Cristiano LM; Li X; Pierce GF; Allen G
Haemophilia; 2016 Jan; 22(1):72-80. PubMed ID: 26218032
[TBL] [Abstract][Full Text] [Related]
40. Target joint resolution in patients with haemophilia A receiving long-term prophylaxis with BAY 94-9027.
Reding MT; Pabinger I; Lalezari S; Santagostino E; Mancuso ME
Haemophilia; 2020 Jul; 26(4):e201-e204. PubMed ID: 32578323
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
